2021 Ranking

Progress continues, yet access to many products still goes unaddressed

Pharmaceutical companies continue to inch forward when it comes to addressing access to medicine in low- and middle-income countries, finds the 2021 Access to Medicine Index, published Tuesday 26 January, 2021. There are signs of progress in how they are integrating pro-access approaches into governance structures, R&D processes and monitoring efforts. Yet initiatives addressing access to specific products still remain focused on a few countries. Pfizer moves into the top five. GSK retains its number one position, yet only slightly ahead of Novartis.

1 GlaxoSmithKline plc
0 1 2 3 4 5
3.67

GlaxoSmithKline plc

Read more
2 Johnson & Johnson
0 1 2 3 4 5
3.33

Johnson & Johnson

Read more
3 Novartis AG
0 1 2 3 4 5
3.26

Novartis AG

Read more
4 Sanofi
0 1 2 3 4 5
2.83

Sanofi

Read more
5 Merck KGaA (Merck)
0 1 2 3 4 5
2.79

Merck KGaA (Merck)

Read more
6 AstraZeneca plc
0 1 2 3 4 5
2.78

AstraZeneca plc

Read more
7 Pfizer Inc.
0 1 2 3 4 5
2.73

Pfizer Inc.

Read more
8 Takeda Pharmaceutical Co. Ltd.
0 1 2 3 4 5
2.71

Takeda Pharmaceutical Co. Ltd.

Read more
9 Roche Holding AG
0 1 2 3 4 5
2.54

Roche Holding AG

Read more
10 Eisai Co. Ltd.
0 1 2 3 4 5
2.11

Eisai Co. Ltd.

Read more
11 Boehringer Ingelheim GmbH
0 1 2 3 4 5
1.77

Boehringer Ingelheim GmbH

Read more
12 AbbVie Inc.
0 1 2 3 4 5
1.75

AbbVie Inc.

Read more
13 Gilead Sciences Inc.
0 1 2 3 4 5
1.71

Gilead Sciences Inc.

Read more
14 Astellas Pharma Inc.
0 1 2 3 4 5
1.32

Astellas Pharma Inc.

Read more
15 Merck & Co., Inc. (MSD)
0 1 2 3 4 5
1.28

Merck & Co., Inc. (MSD)

Read more
16 Bristol Myers Squibb Co.
0 1 2 3 4 5
1.19

Bristol Myers Squibb Co.

Read more
17 Bayer AG
0 1 2 3 4 5
1.01

Bayer AG

Read more
18 Novo Nordisk A/S
0 1 2 3 4 5
0.98

Novo Nordisk A/S

Read more
19 Eli Lilly & Co.
0 1 2 3 4 5
0.88

Eli Lilly & Co.

Read more
20 Daiichi Sankyo Co. Ltd.
0 1 2 3 4 5
0.84

Daiichi Sankyo Co. Ltd.

Read more
0 1 2 3 4 5

The ranking above shows the position and score of each company in the 2021 Index. Click on a company's name to go to its full report card.


Insights

  • 1,073 R&D projects in the pipeline

    The 2021 Index captured 1,073 R&D projects for the 82 diseases, conditions and pathogens in scope i.e., those that cause the greatest burden in low- and middle-income countries. More than 80% of people alive today live in low- and middle-income countries and face the bulk of the global burden imposed by these diseases.

  • 17 companies respond to COVID-19

    During the period of analysis, 17 of the 20 companies in the scope of the Index were active in R&D for COVID-19. A total of 63 projects targeting the virus were in development. The COVID-19 pandemic has demonstrated companies’ ability to rapidly mobilise in the face of priorities. 

  • Over 70% of R&D priorities go unaddressed

    Over 70% (149/211) of the internationally identified R&D priorities for low- and middle-income countries remain unaddressed by the companies in scope. This includes maternal health conditions such as hypertensive disorders of pregnancy and diseases such as Bunyaviral diseases, several diarrhoeal diseases and sexually transmitted infections (STIs).

  • 440 R&D projects offer a clear public health benefit

    The 2021 Index identified 440 projects that target a disease and/or product gap not yet established as a priority by global health stakeholders. These projects are deemed by the Index to offer a clear public health benefit for people living in low-and middle-income countries, e.g., projects aiming for heat stability or with clinical trials running in countries in scope.


Get in touch

Back to top |